MAPT and Alzheimer disease: We compared the proteomic profile of NC A−T+ (normal CSF Aβ42 and abnormal CSF p-tau, A−T+; n = 30) to that of controls (NC A−T−; n = 141), and preclinical Alzheimer’s disease (NC A+T− (n = 65) and NC A+T+ (n = 55)).